EGFR and non-small cell lung carcinoma: Amivantamab (EGFR × c-MET) concurrently inhibits EGFR and mesenchymal-epithelial transition factor (c-MET) signaling, thereby overcoming resistance to targeted therapies in NSCLC [241]; (3) Forced protein complexation: In this approach, the bsAb mediates formation of a complex between two proteins, effectively substituting for a missing or deficient functional molecule.